Three Biotechs That Are Top Takeover Targets

Photo of Alex Sirois
By Alex Sirois Published

Quick Read

  • Viking Therapeutics (VKTX) has a dual GLP-1/GIP agonist in Phase 3 with 4,500+ patients enrolled and oral formulations showing 12.2% body weight reduction, offering a strategic acquisition target with $706M in cash and a $3.69B market cap. Scholar Rock (SRRK) develops apitegromab, a muscle-targeted therapy addressing GLP-1 side effects, with a European launch expected in H2 2026 and an existing Novo Nordisk partnership. Verve Therapeutics (VERV) created a single-dose gene-editing PCSK9 therapy showing 53% mean LDL-C reductions, with Lilly holding an opt-in that may lead to outright acquisition.

  • Eli Lilly and Novo Nordisk are aggressively acquiring earlier-stage therapeutics to defend GLP-1 market dominance and expand beyond weight loss into muscle preservation and cardiovascular disease.

  • It sounds nuts, but SoFi is giving new active invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for yourself (Sponsor)
    DISCLOSURE:
    INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Three Biotechs That Are Top Takeover Targets

© jetcityimage / iStock Editorial via Getty Images

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion. But here’s what you should actually be watching.

The Hot Trade Is Already Crowded

Lilly is a great company at a price that already reflects greatness. Shares trade near $988.87 after a 21.25% one-year run and a staggering 1,465.32% gain over ten years. The decade of compounding has happened. From here, the math gets harder.

Novo Nordisk (NYSE:NVO) is the other half of the GLP-1 duopoly, and it is fighting a different battle. Q4 2025 revenue fell 7.6% year over year, with US Operations down 15%, and management guided 2026 sales and operating profit to decline 5% to 13% at constant exchange rates. CEO Mike Doustdar has acknowledged “pricing headwinds in an increasingly competitive market.” Shares are down 32.11% over the past year.

The interesting move is following where these giants are spending. Lilly’s CEO David Ricks noted four acquisitions announced in Q1 2026 alone: Orna, Centessa, Kelonia, and Ajax. Novo’s BD head conducted 200 meetings at the J.P. Morgan Healthcare Conference, fresh off the $4.7 billion Akero Therapeutics deal. Smart money tends to front-run acquirers rather than pay up at $880 billion.

Three Names On The Shopping List

Viking Therapeutics (NASDAQ:VKTX) is the cleanest strategic fit. Lead asset VK2735 is a dual GLP-1/GIP agonist with both subcutaneous and oral formulations, and Phase 3 VANQUISH-1 was fully enrolled with more than 4,500 patients ahead of schedule. The oral Phase 2 delivered up to 12.2% body weight reduction in 13 weeks. With $706 million in cash and a market cap of just $3.69 billion, Viking is small enough to swallow and dangerous enough that Novo cannot afford to let Lilly grab it. Analysts carry an average target of $92.33 against a current $31.31.

Scholar Rock (NASDAQ:SRRK) plugs the missing piece in the entire GLP-1 thesis. Patients lose muscle alongside fat, and apitegromab is a muscle-targeted therapy with a BLA resubmission expected in 2026 and a European launch planned for the second half of 2026. Scholar Rock is already partnered with Novo Nordisk on the Catalent Indiana facility, an existing tie that makes a takeout straightforward. Market cap sits at $5.55 billion, with analysts at a $57.73 target.

Verve Therapeutics (NASDAQ:VERV) is the most obvious deal of the three. Lilly already has the partnership through VERVE-301 on the LPA program. Lead candidate VERVE-102 is a single-dose gene-editing PCSK9 therapy that produced mean LDL-C reductions of 53% and PCSK9 protein reductions of 60% in the Heart-2 Phase 1b. CEO Sekar Kathiresan calls it a “one dose future” for cardiovascular disease. Lilly holds an opt-in. The math points toward an outright acquisition rather than an opt-in.

What To Watch

The trillion-dollar headline is already crowded. Viking, Scholar Rock, and Verve sit further upstream, where acquirer interest tends to surface first.

Photo of Alex Sirois
About the Author Alex Sirois →

Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.

Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.

At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.

Continue Reading

Top Gaining Stocks

NOW Vol: 38,774,837
D Vol: 25,372,181
CTSH Vol: 8,029,174
FICO Vol: 263,520
IT Vol: 913,496

Top Losing Stocks

STX Vol: 3,305,003
REGN Vol: 2,300,794
GLW Vol: 10,769,045
CTRA Vol: 73,319,495
ENPH Vol: 7,952,518